WHAT’S ON TAP — Congress returns this week from its August recess to grapple with several health care issues — with just three scheduled weeks in Washington left before the elections. Getting significant health care legislation across the finish line isn’t expected until after the elections, but we’re tracking progress on several issues. Here are some key areas we’re watching: Government funding: Lawmakers have until the end of the month to avoid a shutdown. A stopgap measure to keep funding at current levels is likely. House Republicans proposed a measure on Friday to fund the government through March 28, setting up a showdown with Senate Democrats. ACA subsidies: Senate Democrats, looking to box in Republicans, plan to hold a vote on legislation that would permanently extend enhanced subsidies expiring after 2025 for Affordable Care Act coverage, POLITICO’s Robert King reports. The legislation is unlikely to survive a filibuster, but Democrats hope it paints the GOP as an opponent of middle-class subsidies. VA: House Republicans unveiled a $3 billion veterans’ funding patch that’s expected to pass as a standalone bill. The VA has warned lawmakers it will need several billion dollars soon to pay out benefits by Oct. 1. More VA cash could be attached to a stopgap bill. Telehealth: Legislation to extend eased pandemic-era telehealth rules in Medicare could be marked up by the full House Energy and Commerce Committee and maybe even get a floor vote in the coming weeks. Older Americans Act: The Senate Health, Education, Labor and Pensions Committee advanced its version of legislation to reauthorize the Older Americans Act before its expiration at the end of the month. The legislation pays for meals and medical services such as health screenings and transportation to doctors’ offices. It’s unclear whether the House Committee on Education and the Workforce will mark up reauthorization legislation, which it hasn’t released. Insulin: Senate Majority Leader Chuck Schumer said in a letter to Senate colleagues Sunday that there are "opportunities" for bipartisan work on insulin costs but didn't get into specifics. There are multiple proposals to do so. Schumer has pledged to hold a vote but hasn’t yet. CHINA WEEK — The House is expected to vote today on the BIOSECURE Act, which would effectively bar Chinese biotech companies from doing business in the U.S. over fears that China could use genomic data for nefarious purposes. The companies impacted, including Complete Genomics, say lawmakers have bought into misinformation about their work and shouldn’t be included. Rob Tarbox, vice president of product and marketing at Complete Genomics, told Pulse the company’s data is “always local,” and there aren’t ways for it to be compromised. “There’s no denying the ownership of CG is Chinese,” he said. “But then again, we buy a lot of things from China … fundamentally, we don’t … belong in the bill.” The legislation is expected to pass in bipartisan fashion, but there could be some opposition. Rules Committee ranking member Rep. Jim McGovern (D-Mass.) said in a letter obtained by Pulse that he plans to circulate to colleagues that, while he supports shielding Americans’ personal data from foreign adversaries, the bill doesn’t have sufficient due process for the companies. “Congress does not just pick companies to punish at random,” said McGovern, who was sanctioned by China in July. WuXi AppTec, a company named in the bill, announced plans in January to build a major manufacturing facility in Worcester — in McGovern’s district — but that was put on pause. A spokesperson for McGovern said he's been speaking out against China's human rights abuses "for a long time — long before this facility or company existed. … Our team had a problem with this legislation from the start because it's a bad bill." Also this week: The chamber is expected to vote on legislation that would require the Department of Homeland Security to research and craft technology to help law enforcement tackle the illicit trafficking of drugs, including fentanyl.
|
No comments:
Post a Comment